Business
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France, May 15, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy.
About this update from Innate Pharma Sa Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/7663b6b2b894ddda1d60da811c6f097b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l7Lm8XUZyNyNBo05WvIWUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7663b6b2b894ddda1d60da811c6f097b","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.2abDIeQuBXWAatkwPSF5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/7663b6b2b894ddda1d60da811c6f097b","width":1024,"height":512}},"lazy":false},{"type":"text","content":"MARSEILLE, France, May 15, 2025--(BUSINESS WIRE)--Regulatory News:","length":66,"tagName":"p"},{"type":"text","content":"Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy.","length":378,"tagName":"p"},{"type":"text","content":"Abstract details","length":16,"tagName":"p"},{"type":"text","content":"Antitumor characterization of IPH6501, a novel il2v-armed tetraspecific NK cell engager targeting CD20 B cells, in DLBCL and FL patient samples, and in preclinical combination with R-CHOP Abstract Code: PS2004Session: Poster session 2Session Date/Time: Saturday, June 14, 2025, 18:30 – 19:30 CESTMore information can be found on the EHA website.","length":349,"tagName":"p","attribs":{}},{"type":"text","content":"In addition, an abstract related to SAR’514/IPH6401 (developed by Sanofi) was accepted for online publication.","length":110,"tagName":"p"},{"type":"text","content":"The BCMA NK Cell Engager SAR'514 Induces Macrophage-Mediated Phagocytosis which is improved by combination with Evorpacept, a CD47 Blocker, in Multiple Myeloma Abstract Code: PB2850","length":186,"tagName":"p","attribs":{}},{"type":"text","content":"About ANKET®","length":12,"tagName":"p"},{"type":"text","content":"ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for devel...